Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BRNS NYSE:NNVC NASDAQ:NRSN NASDAQ:PBM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBRNSBarinthus Biotherapeutics$0.67$0.60$0.51▼$2.92$27.37M-0.4319,698 shs19,073 shsNNVCNanoViricides$1.55+9.2%$1.10$0.85▼$2.23$33.47M1.54273,638 shs424,399 shsNRSNNeuroSense Therapeutics$0.88+0.3%$0.79$0.63▼$2.60$28.55M1.6155,185 shs80,304 shsPBMPsyence Biomedical$5.59-7.1%$3.90$1.92▼$74.94$6.15M1.787.96 million shs131,434 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBRNSBarinthus Biotherapeutics0.00%+3.08%+13.71%-4.96%-32.31%NNVCNanoViricides0.00%+14.52%+29.09%+61.36%+14.98%NRSNNeuroSense Therapeutics0.00%+6.82%+21.64%-6.69%-13.83%PBMPsyence Biomedical0.00%-8.65%+141.77%+92.33%-77.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBRNSBarinthus Biotherapeutics$0.67$0.60$0.51▼$2.92$27.37M-0.4319,698 shs19,073 shsNNVCNanoViricides$1.55+9.2%$1.10$0.85▼$2.23$33.47M1.54273,638 shs424,399 shsNRSNNeuroSense Therapeutics$0.88+0.3%$0.79$0.63▼$2.60$28.55M1.6155,185 shs80,304 shsPBMPsyence Biomedical$5.59-7.1%$3.90$1.92▼$74.94$6.15M1.787.96 million shs131,434 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBRNSBarinthus Biotherapeutics0.00%+3.08%+13.71%-4.96%-32.31%NNVCNanoViricides0.00%+14.52%+29.09%+61.36%+14.98%NRSNNeuroSense Therapeutics0.00%+6.82%+21.64%-6.69%-13.83%PBMPsyence Biomedical0.00%-8.65%+141.77%+92.33%-77.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBRNSBarinthus Biotherapeutics 2.00Hold$4.00497.01% UpsideNNVCNanoViricides 3.00BuyN/AN/ANRSNNeuroSense Therapeutics 2.60Moderate Buy$8.50865.91% UpsidePBMPsyence Biomedical 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest PBM, NNVC, NRSN, and BRNS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2026BRNSBarinthus Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026PBMPsyence Biomedical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026NRSNNeuroSense Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.003/25/2026NRSNNeuroSense Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.003/17/2026NRSNNeuroSense Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.003/10/2026NRSNNeuroSense Therapeutics Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$3.003/9/2026NRSNNeuroSense Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.00(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBRNSBarinthus BiotherapeuticsN/AN/AN/AN/A$1.63 per shareN/ANNVCNanoViricidesN/AN/AN/AN/A$0.66 per shareN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/A($0.05) per shareN/APBMPsyence BiomedicalN/AN/A$10.35 per share0.54$73.96 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBRNSBarinthus Biotherapeutics-$66.43M-$1.29N/AN/AN/AN/A-63.83%-48.77%N/ANNVCNanoViricides-$8.29M-$0.48N/AN/AN/AN/A-87.90%-78.69%N/ANRSNNeuroSense Therapeutics-$11.12M-$0.54N/AN/AN/AN/AN/AN/A6/22/2026 (Estimated)PBMPsyence Biomedical$1.01M$25.340.22N/AN/AN/AN/AN/AN/ALatest PBM, NNVC, NRSN, and BRNS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/30/2026Q1 2026BRNSBarinthus Biotherapeutics-$0.28-$0.14+$0.14-$0.14N/AN/A3/13/2026Q4 2025BRNSBarinthus Biotherapeutics-$0.40-$0.27+$0.13-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBRNSBarinthus BiotherapeuticsN/AN/AN/AN/AN/ANNVCNanoViricidesN/AN/AN/AN/AN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/AN/APBMPsyence BiomedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBRNSBarinthus BiotherapeuticsN/A6.056.05NNVCNanoViricidesN/A3.442.47NRSNNeuroSense TherapeuticsN/A0.310.31PBMPsyence BiomedicalN/A8.098.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBRNSBarinthus Biotherapeutics25.20%NNVCNanoViricides10.30%NRSNNeuroSense Therapeutics1.04%PBMPsyence Biomedical77.44%Insider OwnershipCompanyInsider OwnershipBRNSBarinthus Biotherapeutics10.70%NNVCNanoViricides3.60%NRSNNeuroSense Therapeutics27.40%PBMPsyence Biomedical3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBRNSBarinthus Biotherapeutics10740.85 million36.48 millionN/ANNVCNanoViricides2021.60 million14.92 millionOptionableNRSNNeuroSense Therapeutics1032.56 million23.64 millionNot OptionablePBMPsyence BiomedicalN/A1.02 million985,000N/APBM, NNVC, NRSN, and BRNS HeadlinesRecent News About These CompaniesPacific Bay Adopts Semi-Annual ReportingMay 4, 2026 | newsfilecorp.comNPsyence Biomedical Ltd. Begins Phase IIb Clinical Trial for NPX-5 Psilocybin Treatment in Cancer PatientsApril 23, 2026 | quiverquant.comQPsyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment DisorderApril 23, 2026 | financialpost.comFPsyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment DisorderApril 23, 2026 | globenewswire.comWhy is PBM stock more than doubling premarket today?April 20, 2026 | msn.comPsyence BioMed Positioned as World’s only Licensed Pharmaceutical Grade Ibogaine Supplier at SourceApril 20, 2026 | financialpost.comFPsyence Biomedical Ltd. Advances Strategic Position in Growing Ibogaine Market with Integrated GMP Manufacturing PlatformApril 20, 2026 | quiverquant.comQPsyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at SourceApril 20, 2026 | globenewswire.comPsyence Biomedical Ltd.: Psyence BioMed Welcomes U.S. Executive Action to Advance Research into IbogaineApril 17, 2026 | finanznachrichten.dePBM stock on track for best session on report of upcoming Trump executive order on psychedelic ibogaineApril 17, 2026 | msn.comPBM stock on track for best week in over 2 years on hopes for upcoming executive order to ease ibogaine researchApril 17, 2026 | msn.comPsyence Biomedical Ltd.April 17, 2026 | cnn.comPsyence Biomedical (PBM) Stock Soars 200%+ on White House Ibogaine Executive OrderApril 17, 2026 | blockonomi.comPsyence BioMed Welcomes U.S. Executive Action to Advance Research into IbogaineApril 17, 2026 | financialpost.comFPsyence Biomedical Ltd. Responds to Anticipated U.S. Executive Order on Ibogaine ResearchApril 17, 2026 | quiverquant.comQPsyence BioMed Welcomes U.S. Executive Action to Advance Research into IbogaineApril 17, 2026 | globenewswire.comPsyence Biomedical (PBM) soars 203.8% as micro-cap momentum builds around recent clinical-trial updates and corporate actionsApril 16, 2026 | quiverquant.comQPsyence Biomedical Expands Australian Psilocybin Trial Network to Five SitesApril 16, 2026 | theglobeandmail.comAurwest Resources Announces Execution of Definitive Agreement on Weaver Lake Gold ProjectApril 14, 2026 | thenewswire.comTPsyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical ActivitiesApril 8, 2026 | financialpost.comFNew MarketBeat Followers Over TimeMedia Sentiment Over TimePBM, NNVC, NRSN, and BRNS Company DescriptionsBarinthus Biotherapeutics NASDAQ:BRNS$0.67 0.00 (0.00%) Closing price 05/8/2026 03:50 PM EasternExtended Trading$0.65 -0.02 (-3.13%) As of 05/8/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.NanoViricides NYSE:NNVC$1.55 +0.13 (+9.15%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$1.56 +0.00 (+0.32%) As of 05/8/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.NeuroSense Therapeutics NASDAQ:NRSN$0.88 +0.00 (+0.34%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$0.88 +0.00 (+0.23%) As of 05/8/2026 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.Psyence Biomedical NASDAQ:PBM$5.59 -0.43 (-7.14%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$5.50 -0.09 (-1.59%) As of 05/8/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
